Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
about
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunctionDoes HIV cause cardiovascular disease?Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients.Dyslipidemia and adherence to the Mediterranean diet in Croatian HIV-infected patients during the first year of highly active antiretroviral therapy.Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults.Lipid profile in HIV/AIDS patients in NigeriaHIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study.Glycemic control in HIV-infected patients with diabetes mellitus and rates of meeting American Diabetes Association management guidelines.Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India.Switching effective antiretroviral therapy: a review.Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy.The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men.The metabolic effects of lopinavir/ritonavir in HIV-negative menHIV therapy, metabolic syndrome, and cardiovascular risk.Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factorsDyslipidemia and its Treatment in HIV Infection.Epidemiology and management of antiretroviral-associated cardiovascular disease.First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study.Dyslipidemia and cardiovascular disease risk profiles of patients attending an HIV treatment clinic in Harare, Zimbabwe.Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review.Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy.Treatment of HIV infection in the older patient.Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.Coronary heart disease risk, dyslipidemia, and management in HIV-infected persons.Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population.Strategies for management and treatment of dyslipidemia in HIV/AIDS.Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group studyChanges in Lipid Profiles of HIV(+) Adults over Nine Months at a Harare HIV Clinic: A Longitudinal Study.Impact of age on markers of HIV-1 diseaseCardiometabolic risk factors among HIV patients on antiretroviral therapy.Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort.Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reversed by glutathione restoration.Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy.Pharmacogenetic information derived from analysis of HLA alleles.Liver steatosis in Chinese HIV-infected patients with hypertriglyceridemia: characteristics and independent risk factorsInfectious and Non-infectious Etiologies of Cardiovascular Disease in Human Immunodeficiency Virus InfectionHormonal contraception and HIV-positive women: metabolic concerns and management strategiesChanges over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.
P2860
Q24802369-70283C8A-FD6F-464B-A196-536B60105816Q28386344-333D22D6-9D20-4916-A73F-1F730ABFDCB0Q33264851-DE738125-6B79-4518-B072-BC646AF2485DQ33455840-ACDC4E79-F810-4623-84D7-E8853A3F957FQ33608017-A86B86D9-265C-43BA-ACFB-E3A5FEF10519Q33747646-C1A4AAFE-5D46-4D70-8CC0-B49EE64603A5Q33936089-A96BEF64-3895-4DF7-957B-11191736696CQ34206446-CFED3B2E-BD7E-48C8-99BD-47764625E983Q34355660-8C3B2748-3293-4A6C-B113-D63868C46D3EQ34539440-53FA550C-D542-49A4-890A-991EEF228C10Q34699194-5FCF83DB-9B7D-45DD-96D1-2982D65A90B3Q34985833-62366507-315D-4003-8259-E6260FC4AD95Q35051199-1B69A9C5-42AD-40B8-A96C-2AC401BB3309Q35166131-855061E9-3B03-4D6E-8ECC-5C9AAA47EB46Q35194394-FDA5919B-876C-44B9-8EC8-0EE7A74699B9Q35194399-C3942B29-4FE1-4351-9348-DFB59712E13DQ35206635-7F236F50-C755-453C-8F3A-BCDDC9A10679Q35293841-FABFD4B1-32F4-479A-ABF3-8302F2585DE3Q35338096-6E00D625-0B7A-499A-BC60-6029D90D84BDQ35397077-39F676DD-6158-4348-A848-8CD4B7E434E1Q35618069-5CC09828-4610-4273-9C02-28EB9A3C2B85Q35805765-BF7427D2-DAB2-4F7C-BF9B-84F68A20362CQ35873877-9080B0C2-4BE7-4982-9D1A-68B59BFA5835Q35917538-48B5377E-CEAA-42C5-96FF-7FF95C048E45Q35968731-BFD65B5E-C8A3-4293-859E-85066B080805Q36025409-957F8E4B-6746-4DAD-9A7B-7EC7583596BEQ36070094-572AD43B-2FFA-4C6B-899F-766B5F4539CFQ36336563-3F99E645-283B-42EA-A40A-F122F29157C0Q36402308-19A20036-FC11-4127-AC59-82E803EDB8D0Q36712750-EB5B0F8E-692B-469A-AD44-0B6F7D423174Q36763762-C283445B-7009-4592-951F-19AA2566ED5CQ36808820-D0C6BFC7-6752-466C-8F74-9A7F3FABDDF0Q36914867-BFE44A44-FAD8-4A58-B77D-BA39BFA3075CQ36980757-8C0CE7B6-65F5-48AE-ACDE-FB7DEBE67542Q37086312-19A6E8A6-2F5D-4E36-87C6-9B98EE73AD30Q37120841-7DD67969-2CD5-4891-A436-7E67F60CDB83Q37152712-BEDFDE19-9D55-461D-B6A6-63FFC14AC1C3Q37195784-E3D2E6D7-3A7C-49B5-BA18-518768E7B775Q37202281-F1DE3A3D-C231-4577-8837-270F3D34E205Q37242966-44FEF3DE-FC50-4B80-A434-E30416785127
P2860
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Nevirapine-containing antiretr ...... nti-atherogenic lipid profile.
@en
Nevirapine-containing antiretr ...... nti-atherogenic lipid profile.
@nl
type
label
Nevirapine-containing antiretr ...... nti-atherogenic lipid profile.
@en
Nevirapine-containing antiretr ...... nti-atherogenic lipid profile.
@nl
prefLabel
Nevirapine-containing antiretr ...... nti-atherogenic lipid profile.
@en
Nevirapine-containing antiretr ...... nti-atherogenic lipid profile.
@nl
P2093
P1433
P1476
Nevirapine-containing antiretr ...... nti-atherogenic lipid profile.
@en
P2093
Atlantic Study Team
F van Leth
H O Molhuizen
J J Kastelein
M van der Valk
P304
P356
10.1097/00002030-200112070-00008
P407
P577
2001-12-01T00:00:00Z